Apretude Approved By FDA To Prevent HIV
Please Subscribe and Get Daily Updates in Your Inbox!!!
The Food and Drug Administration (FDA) approved the world’s first injectable drug for lowering the risk of contracting HIV on 20 December.
Apretude is a medication that can be injected. “Cabogegravir extended-release injectable suspension” is its generic name.
The medicine is an alternative to daily HIV prophylaxis pills such as Truvada and Descovy. According to the Centers for Disease Control and Prevention (CDC), these pills are up to 99 percent effective in preventing HIV transmission through sexual contact. It must, however, be taken daily to be effective.
However, to begin Apretude, clients are given two doses one month apart. They will be given an injection every two months after that.
This injection will be crucial to combat the HIV epidemic in the United States.
It will also benefit high-risk individuals and specific groups for whom taking daily medicine is difficult or impossible.
The list price for Apretude is $3,700 per dose. In the United States, it is expected to ship to wholesalers and specialty distributors in 2022.
Before commencing the injections, HIV patients will be given an oral formulation of cabotegravir called Vocabria to take daily for four weeks to determine how well they handle it.
Before commencing Apretude, patients must be tested for HIV and found to be negative.
To avoid the possibility of developing drug-resistant HIV, they must also be verified negative before each injection.